Head and Neck Cancer Therapeutics Market to Witness Healthy Growth through 2025
Increasing cases of head and neck cancer and spike in demand
for combination therapy to drive global head and neck cancer therapeutics market
According
to TechSci Research report, “Global
Head
and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy and blood
tests, Imaging, Endoscopy, Others), By Treatment Type (Chemotherapy, Surgery, Radiation
Therapy (External Radiation Therapy, Internal Radiation Therapy), Targeted
Therapy, Immunotherapy), By Disease Indication (Laryngeal Cancer, Lip and Oral
Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Salivary Gland
Cancer, Others), By Route of Administration (Oral, Injectable), By Therapeutic
Class (PD Inhibitors, Microtubule Inhibitors, EGFR Inhibitors), By End User (Hospitals, Specialty Clinics,
Ambulatory Surgical Centers), By Region, Forecast & Opportunities, 2025”, the market is anticipated to witness robust CAGR during
the forecast period. The growth in global head and neck cancer therapeutics market
can be attributed to rising prevalence of head and neck cancer around the world
and growing geriatric population, which is more vulnerable to cancer. According
to Union for International Cancer Control (UICC), around 300,000 deaths happen
every year due to head and neck cancer. This is leading to growing awareness
and increasing demand for head and neck cancer therapeutics. In addition to
this, extensive R&D activities to develop ideal therapeutic and growing
demand for combination therapies to treat head and neck cancer are expected to
augment the market growth through 2025.
Moreover, governments and private organizations’ initiative
to provide improved healthcare service and beneficial healthcare reforms are
supporting the growth of global head and neck cancer therapeutics market. Also,
growing popularity of immunotherapy for head and neck cancer treatment is
expected to provide huge growth opportunities for pharmaceutical companies.
Furthermore, cancer awareness programs and early cancer diagnosis are acting as
some other key growth drivers for head and neck cancer therapeutics market.
Browse
XX market data Tables and XX Figures spread through XXX
Pages and an in-depth TOC on "Global Head and Neck Cancer Therapeutics Market"
https://www.techsciresearch.com/report/head-and-neck-cancer-therapeutics-market/5056.html
The global
head and neck cancer therapeutics market is segmented based on diagnostic
methods, treatment type, disease indication, route of administration,
therapeutic class, end user and region. Based on disease indication, the market
can be segmented into laryngeal cancer, lip and oral cavity cancer,
nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer and others.
Among them, lip and oral cavity cancer is expected to contribute largest share
through 2025 due to large patient pool affected by lip and oral cancer globally.
Based
on therapeutic class, global head and neck cancer therapeutics market can be
segmented into PD inhibitors, microtubule inhibitors and EGFR inhibitors. Among
them, PD inhibitor drug class is expected to grow significantly during the
forecast period owing to new product launches.
Major players operating in the global
head and neck cancer therapeutics market include AstraZeneca Plc., Acceleron
Pharma, Inc., Astellas Pharma Inc., AB Science SA, Bristol-Myers Squibb
Company, Boston Biomedical, Inc., Eli Lilly and Company, F. Hoffmann-La Roche
Ltd. (Genentech, Inc.,), Fresenius Medical Care AG & Co. KGaA, Sun
Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Merck
& Co., Inc., Pfizer Inc., Sanofi S.A., Bayer AG and AbbVie Inc. The players
are undergoing extensive R&D activities to develop new therapeutic drugs
and increase their global market share.
Download
Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5056
Customers
can also request for 10% free customization on this report.
“North
America is expected to contribute to largest share in global head and neck
cancer therapeutics market as United States is witnessing high prevalence
HPV-induced cancers. However, Asia Pacific is expected to register fastest CAGR
during the forecast period owing to rising incidences of head & neck cancer.
The risk factors such as increase in cigarette smoking and usage of tobacco is
also making the region a lucrative market for drug manufacturing companies,” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based
global management consulting firm.
“Global Head and Neck Cancer Therapeutics Market By Diagnostic
Methods (Biopsy and blood tests, Imaging, Endoscopy, Others), By Treatment Type
(Chemotherapy, Surgery, Radiation Therapy (External Radiation Therapy, Internal
Radiation Therapy), Targeted Therapy, Immunotherapy), By Disease Indication
(Laryngeal Cancer, Lip and Oral Cavity Cancer, Nasopharyngeal Cancer,
Oropharyngeal Cancer, Salivary Gland Cancer, Others), By Route of
Administration (Oral, Injectable), By Therapeutic Class (PD Inhibitors,
Microtubule Inhibitors, EGFR Inhibitors), By End User (Hospitals, Specialty Clinics,
Ambulatory Surgical Centers), By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of global head
and neck cancer therapeutics market and provides statistics & information
on market size, structure and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges and opportunities in global
head and neck cancer therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]